Introduction
Protein tyrosine phosphatases (PTPs), in coordination with protein tyrosine kinases, play essential regulatory roles in diverse cellular activities by modulating the phosphorylation state of target proteins [1] . Dysregulation of PTPs is associated with a multitude of diseases, such as cancers, diabetes, allergic inflammation, and nervous system diseases [2] [3] [4] [5] [6] [7] . Many members of the PTP family have been identified as potential therapeutic targets [8] . The human genome contains 107 PTP genes, with the Class I cysteinebased PTP genes constituting the largest group. This group can be further subdivided into 61 dual-specificity phosphatases and 38 tyrosine-specific PTP genes, the 'classical PTPome'. Classical PTPs have been further subdivided into receptor (R1-R8) and non-transmembrane (NT1-NT9) subgroups [9, 10] . Twelve receptor PTPs contain two catalytic domains (tandem domains), while the remaining PTPs only have a single catalytic phosphatase domain. In tandem-domain receptor protein tyrosine phosphatases (RPTPs), it is the PTP (D1) domain adjacent to the plasma membrane that displays catalytic activity while the PTP (D2) domain is either inactive or has negligible catalytic activity [10] .
PTP-sigma (PTPs) belongs to the Type R2A sub-family of receptor PTPs. Other members of this sub-family include the human leukocyte common antigen-related PTP (LAR), PTPdelta (PTPd), the invertebrate ortholog Dlar, DPTP69D in Drosophila, PTP-3 in Caenorhabditis elegans, and HmLAR1/2 in Hirudo medicinalis [11] . PTPs and other members of the Type R2A sub-family play vital roles in the central and peripheral nervous systems by providing and responding to axon guidance, synaptic function, and nerve repair [7,12 -15] . By using brain lysate from PTPs-deficient mice, in combination with substrate trapping experiments, N-cadherin and b-catenin were identified as substrates of PTPs, which led to a model of PTPs-regulated axon growth involving a cadherin/catenindependent pathway [16] . In addition, PTPs inhibits axonal regeneration and the rate of axon extension [17] . The rate of nerve regeneration is enhanced after trauma (e.g., crush or transection) in PTPs-deficient mice [18] . In addition, PTPs acts as a receptor for chondroitin sulfate proteoglycan, an inhibitor of neural regeneration, which clarifies the nerve regeneration inhibitory mechanism of chondroitin sulfate proteoglycan [19] . The contributions to axon growth and regeneration make PTPs become an interesting and important phosphatase.
Therefore, investigation of the activity and structure of PTPs may provide clues for further understanding this protein. Although the three-dimensional structure of human PTPs tandem phosphatase domains has been determined at 2.0 Å [11] , limited studies about mouse PTPs structure and in vitro activity have been done. Here, we report the crystal structure of mouse PTPs tandem phosphatase domains at 2.4 Å resolution and present a straightforward structural insight as well as in vitro activity basis for homology and difference between mouse PTPs and human PTPs. It was found that mouse PTPs and human PTPs have different substrate specificities targeting O-methyl fluorescein phosphate (OMFP) and p-nitrophenylphosphate ( pNPP). 2) were cloned with the pET21b-mPTPs-D1D2 and the pET21b-hPTPs-D1D2 as templates respectively, using the same clone sites with mPTPs-D1D2 plasmid. The mutants of mPTPs-D1 were constructed using the Quik-Change Site-directed Mutagenesis Kit (Stratagene, La Jolla, USA) as directed by the manufacturer with the pET21b-mPTPs-D1 as the template. All constructs were verified by DNA sequencing.
Materials and Methods

Expression and purification of recombinant proteins
The recombinant plasmids were transformed into Escherichia coli strain BL21(DE3)pLysS cells. The cells containing plasmids were grown at 378C in Luria-Bertani medium supplemented with 50 mg/ml of ampicillin till OD 600 value reached 1.0 and then induced with 0.1 mM isopropyl b-D-1-thiogalactopyranoside for further 10 h at 308C. The cells were harvested by centrifugation and resuspended in buffer A (20 mM Tris-HCl, pH 8.0). The suspension was then lysed by sonication on ice. After centrifugation, the resultant supernatant was loaded onto the Ni-NTA agarose (Qiagen, Hilden, Germany), which was pre-equilibrated with buffer A. Then the His6-tagged proteins were eluted with an elution buffer (buffer A supplemented with 50 mM imidazole). The eluted fractions were then loaded onto a HiTrap Q anion exchange column (GE Healthcare, Wisconsin, USA) and the target protein was eluted in fractions containing buffer A with 300-500 mM NaCl. For crystallization, the eluted fractions were pooled together and further purified by gel filtration with a Sephacryl S-200 column (GE Healthcare) preequilibrated with buffer B [10 mM Hepes, pH 7.5, 150 mM NaCl, 10 mM methionine, 10% glycerol, and 2 mM DL-dithiothreitol (DTT)]. Fractions containing target proteins were pooled and concentrated. For kinetic assay, target proteins eluted from the HiTrap Q anion exchange column were desalted into buffer C (20 mM Tris-HCl, pH 8.0, 260 mM NaCl, and 2 mM DTT) with a HiPrep 26/10 desalting column (GE Healthcare). Protein concentrations were determined by the Bradford method with bovine serum albumin as the standard. Protein purities and homogeneities were determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
Crystallization and diffraction data collection Crystallization was performed at 48C using the hangingdrop vapor diffusion method. The protein samples were concentrated to 8 mg/ml before crystallization. Beanshaped crystals were grown in drops containing equal volumes (2 ml) of the protein mixture solution and the reservoir solution (0.08 M malic acid or 0.08 M succinic acid, pH 7.0, 15% PEG3350) to the maximum size in 2-3 days. Diffraction data were collected to 2.4 Å resolution from flash-cooled crystals at 21768C at beamline BL-17U in the Shanghai Synchrotron Radiation Facility (Shanghai, China) and processed with the HKL2000 suite [20] . A summary of the diffraction data statistics is shown in Table 1 .
Structure determination and refinement The structure was solved with the molecular replacement method implemented in the program suite CCP4 using the structure of the human PTPs (PDB code 2FH7) as the model. The initial structure refinement was carried out with program CNS [21, 22] and REFMAC5 following the standard protocol. Model building was performed manually with the program COOT [23] . Throughout the refinement, 5% of randomly chosen reflection were set aside for free R factor Structural insights into the homology and differences between mouse and human PTPs monitor. The final stereochemical quality of structural model was checked by PROCHECK. A summary of structure refinement is listed in Table 1 .
Activity assay and kinetic study The activity assay of PTPs was carried out in a 50-ml system containing 50 mM CH 3 COONa, pH 5.0, 2 mM DTT, 1 mM ethylenediaminetetraacetic acid, 0.1% CHAPS, 10 mM OMFP or 200 mM pNPP, and different PTPs concentrations (25 nM mPTPs-D1D2, 100 nM hPTPs-D1D2, 37.6 nM mPTPs-D1, 934 nM hPTPs-D1, and 37.6 nM mPTPs-D1 mutants). The rate of degradation product, OMF, was shown with the change of emitted light at 535 nm under the exciting light at 485 nm, which was monitored continuously for 5 min, and the initial rate of degradation was determined using the early linear region of the enzymatic reaction curve. Continuous kinetic monitoring was performed in clear 384-well plates (Corning, Lowell, USA) on Envision (Pelkin Elmer Life Sciences, Downers Grove, USA) controlled by Wallac EnVision Manager at room temperature.
The kinetic parameters were analyzed by GraphPad Prism 5.0 (GraphPad Software, La Jolla, USA) and presented as the mean + SD from at least three independent experiments. The K m value was calculated in GraphPad Prism using non-linear regression analysis and enzyme kinetics (Michealis -Menten or k cat ) equation.
Results
Structure of mPTPs-D1D2
To crystallize mPTPs-D1D2, the plasmid carrying mPTPs-D1D2 gene was constructed. The recombined protein was purified to crystallization level through the Ni-NTA agarose followed by Q-Sepharose anion exchange and gel filtration S-200 chromatography. Then mPTPs-D1D2 was crystallized and its structure was solved by molecular replacement at 2.4 Å resolution (PDB code 3SR9). mPTPs-D1D2 is a monomer in the crystalline state and also behaves as a monomer in solution as judged by analytical gel filtration chromatography (data not shown), which is constant with that of hPTPs-D1D2 [11] . In the molecule, the fragment contains two well-defined PTP domains, D1 and D2, connected by a 10-residue linker ( Fig. 1) . Both phosphatase domains have the same overall tertiary fold as seen in the previously determined PTP structures [11,24 -26] . The main features of each domain include a highly twisted eight-stranded mixed b-sheet flanked by four a-helices on one side and two on the other (Fig. 1) . The active site topologies within the two mPTPs domains D1 and D2 are very similar to each other and also similar to the other PTPs, all with a cradle for phosphopeptide binding surrounded by four loop regions (Fig. 1) . However, Asp-1516 from the WPD loop in D1 changes into Glu-1805 in D2 and Tyr-1381 from the KNRY loop in D1 changes into Leu-1670 in D2, which may account for the altered activity of D2 [24] . As there is no substrate or substrate analogs in the crystal structure, the catalytic (WPD) loop is open, which is consistent with the published crystal structure of hPTPs-D1D2 [11] .
Structural comparison of mPTPs-D1D2 and other PTPs
After the determination of the crystal structure of mPTPs-D1D2, structural comparison was made between the two structures of mPTPs-D1D2 (PDB code 3SR9) and hPTPs-D1D2 (PDB code 2FH7). The overall structures were proved to be very similar, superimposing with a root mean square deviation (RMSD) of 0.45 Å for 517 equivalent Ca atoms. Moreover, the structure of mPTPs-D1D2 almost overlaps with hPTPs-D1D2 (Fig. 1) . In the overlay shown in Fig. 1 , the active sites of mPTPs-D1D2 and hPTPs-D1D2 are highly structurally conserved. In particular, the residues that form the WPD loop (containing the catalytic acid D), KNRY loop ( participating in phosphotyrosine recognition), CX 5 R catalytic site motif (capable of 
Structural insights into the homology and differences between mouse and human PTPs binding the phosphate analog tungstate), as well as the interface participating in interaction between D1 and D2 domains are strictly overlapped and the regions around them are nearly invariant. However, there are still some tiny structural differences between mPTPs-D1D2 and hPTPs-D1D2. For example, the first b-sheet (residues 1408-1411 aa) of mPTPs-D1D2 is shorter than the corresponding b-sheet (residues 1446-1454 aa) of hPTPs-D1D2. Residues 1391-1393 of mPTPs-D1D2 form a loop but the corresponding residues 1432-1434 in hPTPs-D1D2 form a b-sheet. Residues 1337-1358 of mPTPs-D1D2 form two helices but the corresponding residues 1378-1399 in hPTPs-D1D2 form only one helix. In addition, in D2 domains, residues 1656-1668 of mPTPs-D1D2 form a loop but the corresponding residues 1697-1709 in hPTPs-D1D2 form two helices (Fig. 2) . These structural similarities and differences between the two species PTPs-D1D2 may bring about corresponding activity similarities or differences. Besides structural comparison of mPTPs and hPTPs, we compared the crystal structure of mPTPs with other tandem phosphatase domains of LAR, CD45, and PTPg. As shown in Fig. 3 , the overall organization of the PTPs, LAR, CD45, and PTPg tandem phosphatase domains is very similar. However, it is remarkable that the WPD loop (catalytic loop) of PTPs is open due to no substrate binding in the crystal structure, which is the same to LAR and PTPg. But the WPD loop of CD45 is closed because of substrate binding. Detailed comparison of residues participating in catalytic process suggests that the catalytic acid (D) of WPD loop in PTPs, LAR, and PTPg is outward of the active center but the catalytic acid (D) of CD45 is inward to the active center, which makes it easier for itself to provide proton for catalytic process. In addition, in PTPs, LAR, and PTPg, the position of the basic residue (R) that is important for both substrate binding and transition state stabilization is different from that in CD45. This difference is almost certainly due to substrate binding. It could be speculated from the structural comparison that residues in PTPs active center, especially the catalytic acid (D) and basic residue (R), are probably to shift in the same way during catalytic process.
Specific activity and kinetic parameters differences between mPTPs-D1D2 and hPTPs-D1D2 toward OMFP as the substrate Structural comparison between mPTPs-D1D2 and hPTPs-D1D2 suggests that although the structure of mPTPs-D1D2 is very similar to that of hPTPs-D1D2, there are still some tiny structural differences. To investigate whether these differences could bring about activity differences, the recombinant proteins mPTPs-D1D2 and hPTPs-D1D2 were purified to high purity and homogeneity through the Ni-NTA agarose followed by Q-Sepharose anion exchange chromatography (Fig. 4) . Then their activities and kinetic parameters were measured under the same assay conditions (details described in Materials and Methods). Specific activities are relatively high, which are Structural insights into the homology and differences between mouse and human PTPs Structural insights into the homology and differences between mouse and human PTPs consistent with previous studies [25] . Surprisingly, mPTPs-D1D2 has 25-fold higher specific activity than hPTPs-D1D2 does. In addition, kinetic parameters of mPTPs-D1D2 and hPTPs-D1D2 were also determined. As shown in Fig. 4 and Table 2 , there is almost no difference in K m between them, which is consistent with the structural similarities in CX 5 R catalytic site motifs deep in the active sites. However, k cat of mPTPs-D1D2 is 25 folds higher than that of hPTPs-D1D2. The specific activity difference between mPTPs-D1D2 and hPTPs-D1D2 might be caused by the difference in catalytic efficiency rather than in the substrate binding ability.
Specific activity and kinetic parameters differences between mPTPs-D1 and hPTPs-D1 toward OMFP as the substrate To clarify the catalytic efficiency difference between mPTPs-D1D2 and hPTPs-D1D2, we initially aligned the amino acid sequences of mPTPs-D1D2 and hPTPs-D1D2. However, sequences alignment of mPTPs-D1D2 and hPTPs-D1D2 showed 96% identity, and residues among active center including WPD loop, KNRY loop, and CX 5 R loop are entirely identical. There are only 20 different residues scattered in the sequences (Fig. 5) . It was reported that it is the PTP (D1) domain adjacent to the plasma membrane that displays catalytic activity while the PTP (D2) domain is either inactive or has negligible catalytic activity in tandem-domain RPTPs [10] . To investigate whether the activity difference in mPTPs-D1D2 and hPTPs-D1D2 is induced by mPTPs-D1 and hPTPs-D1 activity difference, mPTPs-D1 and hPTPs-D1 were purified to have crystallization grade purity (Fig. 6) and their specific activities were measured using the same assay as the mPTPs-D1D2. In agreement with the specific activity difference between mPTPs-D1D2 and hPTPs-D1D2, the specific activity of mPTPs-D1 is 19 folds higher than that of hPTPs-D1. Furthermore, the kinetic parameter differences between mPTPs-D1 and hPTPs-D1 are similar to those between mPTPs-D1D2 and hPTPs-D1D2. As shown in Fig. 6 and Table 3 , K m of mPTPs-D1 is 1.6 folds as high as that of hPTPs-D1, but the k cat of mPTPs-D1 is 20 folds as much as that of hPTPs-D1. Therefore, it could be speculated that the specific activity difference between mPTPs-D1D2 and hPTPs-D1D2 toward OMFP as the substrate may be resulted from the difference between mPTPs-D1 and hPTPs-D1. 
Structural insights into the homology and differences between mouse and human PTPs
Specific activity comparison among mPTPs-D1 wild type and mutants Since the specific activity of mPTPs-D1 is 19 folds higher than that of hPTPs-D1 and sequences alignment suggests that 11 amino acids are different between mPTPs-D1 and hPTPs-D1 (Fig. 5) , we suspected that the different amino acids could induce specific activity or kinetic parameters differences. To solve this problem, the different amino acids in mPTPs-D1 were mutated to corresponding amino acids in hPTPs-D1 and recombined proteins were purified to have crystallization grade purity (Fig. 7) . Then the specific activities were measured using the same assay as in wild-type mPTPs-D1. As shown in Fig. 7 , there is almost no difference in the specific activity between wild type and mutants of mPTPs-D1. The specific activities of these mutants vary from 10% to 20% compared with that of the wild type. The most changed mutant is R1416C, of which the specific activity decreases by 50%. Therefore, most of the single amino acid change cannot induce significant activity differences and only the mutant R1416C may bring some activity differences.
Specific activity and kinetic parameters of mPTPs-D1, mPTPs-D1D2, hPTPs-D1, and hPTPs-D1D2 toward pNPP as the substrate mPTPs-D1 mutants have no significant activity differences when compared with the wild type, while the specific activity of mPTPs-D1 is 19 folds higher than hPTPs-D1 specific activity. In order to further confirm the specific activity difference between mPTPs-D1 and hPTPs-D1, another widely used PTP substrate pNPP was used to measure the specific activities and kinetic parameters of mPTPs-D1 and hPTPs-D1. Interestingly, specific activity, K m , and k cat of mPTPs-D1 are almost the same with those of hPTPs-D1 (Fig. 8 and Table 4) , with ,30% variation. Structural insights into the homology and differences between mouse and human PTPs
These similarities between mPTPs-D1 and hPTPs-D1 demonstrate high conservation of PTPs in mouse and human, which is in accordance with structural similarities between mPTPs-D1 and hPTPs-D1. This result is in accordance with results of structural comparison as well as activity comparison between mPTPs-D1 wide type and mutants. But it does not agree with results from activity difference when using OMFP as the substrate. The discrepancy indicates that mPTPs-D1 and hPTPs-D1 have different substrate specificities. Since specific activity of mPTPs-D1 and hPTPs-D1 is similar toward pNPP as the substrate, it could be speculated that the activity of mPTPs-D1D2 should be identical with that of hPTPs-D1D2 toward pNPP as the substrate. To compare the activities of mPTPs-D1D2 and hPTPs-D1D2, their activities were also measured toward pNPP as the substrate. Their activities and kinetic parameters were measured using the same activity assay method (details described in Materials and Methods). Consistent with those of D1, mPTPs-D1D2 has almost the same specific activity and kinetic parameters as hPTPs-D1D2 does. The specific activity and kinetic parameters variations between mPTPs-D1D2 and hPTPs-D1D2 are only 10% (Fig. 9 and Table 5 ). All these similarities are consistent with structural similarities between the two enzymes. In conclusion, specific activity and kinetic parameters similarities between mPTPs-D1 and hPTPs-D1 as well as mPTPs-D1D2 and hPTPs-D1D2 toward pNPP as the substrate are consistent with conservations of PTPs intradomains in mouse and human that could be drawn from sequences alignment of Structural insights into the homology and differences between mouse and human PTPs mPTPs-D1D2 and hPTPs-D1D2. In addition, different results from pNPP and OMFP suggest that mPTPs and hPTPs have different substrate specificities, which indicate that there are tiny differences between mouse PTPs and human PTPs.
Discussion
PTPs plays an important role in the development and regeneration of the nervous system. Here we first reported the well-defined crystal structure of mPTPs-D1D2 at 2.4 Å resolution. Then we compared the crystal structures of mPTPs with hPTPs and found that they have similarities and differences. Furthermore, we also found that mPTPs-D1D2 has 25-fold higher specific activity when compared with human hPTPs-D1D2. However, there is no significant activity difference between the mouse and the human enzyme detected with pNPP as the substrate. mPTPs-D1D2 and hPTPs-D1D2 as well as mPTPs-D1 and hPTPs-D1 have different substrate specificities toward OMFP and pNPP as substrates. The crystal structure of mPTPs tandem phosphatase domains we reported here is a monomer in the crystalline state and also behaves as a monomer in solution as judged by analytical gel filtration chromatography (data not shown). This result supports a previous study, in which hPTPs-D1D2 was reported as a monomer in both crystalline and solution [11] . However, it has been suggested that PTPs forms homodimers in the cell and that dimerization is required for ligand binding [27] . The apparent discrepancy between these cell-based results and biophysical studies may be explained by demonstrations that dimerization depends, at least in part, on interactions involving the transmembrane segment [27] , which is absent from the D1D2 construct used for crystallographic and biophysical studies.
Structural comparison suggests that the crystal structure of mPTPs-D1D2 is very similar to that of hPTPs-D1D2, with a RMSD of 0.45 Å for 517 equivalent Ca atoms. However, there are still some differences between the two structures. Of these differences, the first b-sheet (residues 1408-1411 aa) of mPTPs-D1D2 is shorter than the Structural insights into the homology and differences between mouse and human PTPs corresponding b-sheet (residues 1446-1454 aa) of hPTPs-D1D2. Residues 1391-1393 of mPTPs-D1D2 form a loop but the corresponding residues 1432-1434 in hPTPs-D1D2 form a b-sheet. Those residues form the back side of the active site and are required for proper folding. Residues 1337-1358 of mPTPs-D1D2 form two helices but the corresponding residues 1378-1399 in hPTPs-D1D2 form only one helix, which is beside the active center. These differences make the active center of mPTPs more flexible than that of hPTPs and make it easier for mPTPs to hydrolyze the more complex substrate, such as OMFP. Therefore, these differences are probably one of the reasons for higher specific activity of mPTPs targeting OMFP as the substrate.
It could be speculated that mPTPs-D1D2 should have similar activity with hPTPs-D1D2 from sequences alignment. However, mPTPs-D1D2 has 25-fold higher activity than hPTPs-D1D2 does toward OMFP as the substrate. Furthermore, mPTPs-D1 also has 19-fold higher activity than hPTPs-D1 does against OMFP. But there are almost no activity differences when detected with pNPP as substrate. It seems to be a discrepancy. Different substrate specificities on OMFP and pNPP may explain this discrepancy. As shown in Tables 2 and 5 , mPTPs-D1D2 has 600-fold higher activity with OMFP than that with pNPP. However, hPTPs-D1D2 has only 25-fold higher activity with OMFP than that with pNPP. The 24-fold difference in the ratios of mPTPs-D1D2 and hPTPs-D1D2 with these two substrates suggests that mPTPs-D1D2 and hPTPs-D1D2 have significant substrate specificities. Comparison of OMFP structure with pNPP structure, it Structural insights into the homology and differences between mouse and human PTPs could be found that the structure of OMFP is more complex. Structural differences between mPTPs-D1D2 and hPTPs-D1D2 may result in different position of OMFP between mouse and human PTPs in the enzyme-substrate complex and hence the different catalytic activity toward OMFP. But it is not for pNPP due to its simple structure. The specific activity and k cat differences between mPTPs-D1 and hPTPs-D1 toward OMFP as the substrate are shown the same with those of mPTPs-D1D2 and hPTPs-D1D2. The different substrate specificities between mPTPs-D1D2 and hPTPs-D1D2 also indicate that PTPs may have different substrate tendentiousness in physiological state. Sequences alignment suggests that there are still 20 residues that are different between mPTPs-D1D2 and hPTPs-D1D2. Mutagenesis of some of these residues did not identify any other particular single residue that would be responsible for the activity difference except for the mutant R1416C, of which the specific activity decreases by 50%. However, this does not mean these different residues do not affect structures or activities. It is possible that activity differences between mPTPs-D1D2 and hPTPs-D1D2 or mPTPs-D1 and hPTPs-D1 are not induced by a single amino acid but by the co-action of these residues. Therefore, combined mutants of several amino acids may induce activity differences and further combined mutation is ongoing. For R1416C, of which the specific activity decreases by 50%, it is in a loop in the crystal structure of mouse PTPs. Therefore, it has some flexibility and mutation from arginine in mouse to cysteine in human may bring about some structural differences, which results in activity differences. But there is a singlenucleotide polymorphism (SNP) in this position in the crystal structure of human PTPs (PDB code 2FH7), in which the corresponding residue C1419 in human PTPs used for activity detection is mutated into R1457 in the crystal structure of human PTPs (PDB code 2FH7) used for structural comparison. As a result, the residue in this position of mPTPs and hPTPs used for structural comparison are both arginine and the structural differences between mPTPs and hPTPs without SNP in this position caused by this residue difference (R1416 in mouse and C1419 in human) can not be 'observed' in the structural comparison.
In conclusion, we report the well-defined crystal structure of mPTPs tandem phosphatase domains. Structural comparison suggests that although mPTPs-D1D2 and hPTPs-D1D2 are very similar to each other, there are some tiny differences. In addition, mPTPs-D1D2 has in vitro activity differences with hPTPs-D1D2 against OMFP substrate but their activities are consistent targeting pNPP as the substrate. mPTPs and hPTPs have different substrate specificities toward OMFP and pNPP as substrates. Therefore, it could be concluded that mPTPs has high homology with hPTPs, but there are still some differences between them.
